Journal article
Nasal priming by a murine coronavirus provides protective immunity against lethal heterologous virus pneumonia
JCI Insight, Vol.3(11), e99025
2018
DOI: 10.1172/jci.insight.99025
PMCID: PMC6124400
PMID: 29875310
Abstract
The nasal mucosa is an important component of mucosal immunity. Immunogenic particles in inspired air are known to activate the local nasal mucosal immune system and can lead to sinonasal inflammation; however, little is known about the effect of this activation on the lung immune environment. Here, we showed that nasal inoculation of murine coronavirus (CoV) in the absence of direct lung infection primes the lung immune environment by recruiting activated monocytes (Ly6C + inflammatory monocytes) and NK cells into the lungs. Unlike infiltration of these cells into directly infected lungs, a process that requires type I IFN signaling, nasally induced infiltration of Ly6C + inflammatory monocytes into the lungs is IFN-I independent. These activated macrophages ingested antigen and migrated to pulmonary lymph nodes, and enhanced both innate and adaptive immunity after heterologous virus infection. Clinically, such nasal-only inoculation of MHV-1 failed to cause pneumonia but significantly reduced mortality and morbidity of lethal pneumonia caused by severe acute respiratory syndrome CoV (SARS-CoV) or influenza A virus. Together, the data indicate that the nose and upper airway remotely prime the lung immunity to protect the lungs from direct viral infections. Nasal priming with a pathogen in the absence of any lung infection protects against lethal heterologous virus challenge.
Details
- Title: Subtitle
- Nasal priming by a murine coronavirus provides protective immunity against lethal heterologous virus pneumonia
- Creators
- Xiaoyang Hua - Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USARahul Vijay - Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USARudragouda Channappanavar - Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USAJeremiah Athmer - Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USADavid K Meyerholz - Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USANitin Pagedar - Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USAStephen Tilley - Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USAStanley Perlman - Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
- Resource Type
- Journal article
- Publication Details
- JCI Insight, Vol.3(11), e99025
- DOI
- 10.1172/jci.insight.99025
- PMID
- 29875310
- PMCID
- PMC6124400
- NLM abbreviation
- JCI Insight
- ISSN
- 2379-3708
- eISSN
- 2379-3708
- Publisher
- American Society for Clinical Investigation
- Grant note
- RO1 NS36592 / ; 2T32DC000040-21 / ; 1R21AI096139-01A1 / ; RO1ES025198 / ;
- Language
- English
- Date published
- 2018
- Academic Unit
- Microbiology and Immunology; Stead Family Department of Pediatrics; Pathology; Iowa Neuroscience Institute; Otolaryngology; Infectious Disease (Pediatrics)
- Record Identifier
- 9983777352002771
Metrics
25 Record Views